Akero Therapeutics (AKRO) Peer Comparison

$54.65

$0.00 (0.00%)

As on 09-Dec-2025 09:30EDT

Market cap

$4,499 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

4.7

Div. Yield

0 %

Edit

	Akero Therapeutics (AKRO)	Leap Therapeutics (LPTX)	Adverum Biotechnologies (ADVM)
Market cap ($ Mln)	4,499	116	96
Revenue ($ Mln)	--	0	-4
Net Profit ($ Mln)	-292.82	-98.22	-204.39
Net Margin (%)	-7,320,500.00	-22,170.65	5,677.56
RoE (%)	-28.69	-834.64	--
Price to Earnings	--	--	--
Price-To-Book	4.70	27.25	0.93

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Akero Therapeutics (AKRO)	Leap Therapeutics (LPTX)	Adverum Biotechnologies (ADVM)
Operating Revenue	0.00	0.44	-3.60
Cost of Revenue	0.00	31.01	1.68
Gross Profit	-0.02	-0.01	1.00
Operating Expenses	330.02	75.07	206.85
Operating Profit (EBIT)	-330.02	-105.64	-207.32
Other Income	0.00	0.00	0.00
Profit before Tax	-292.82	-100.25	-204.39
Provision for Tax	0.00	-2.30	-0.09
Profit after Tax (Net Income)	-292.82	-98.22	-204.39
Minority Interest	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00

Liabilities ($ Mln)

	Akero Therapeutics (AKRO)	Leap Therapeutics (LPTX)	Adverum Biotechnologies (ADVM)
Shareholder's Funds	957.64	2.70	-55.65
Minority Interest	0.00	0.00	0.00
Non-Current Liabilities	0.29	0.00	83.31
Current Liabilities	47.65	8.70	44.75
Total Liabilities	825.89	49.12	179.84

Assets ($ Mln)

	Akero Therapeutics (AKRO)	Leap Therapeutics (LPTX)	Adverum Biotechnologies (ADVM)
Non-Current Assets	251.04	0.90	43.49
Current Assets	754.54	10.50	28.91
Total Assets	825.89	49.12	179.84
Total Debt*	1.16	0.04	88.94
Net Current Assets	706.88	0.00	-15.84

Cashflow ($ Mln)

	Akero Therapeutics (AKRO)	Leap Therapeutics (LPTX)	Adverum Biotechnologies (ADVM)
Cash From Operating Activities	-230.11	-60.30	-92.46
Cash Flow from Investing Activities	-109.71	--	-41.89
Cash from Financing Activities	445.85	37.18	120.00
Net Cash Inflow / Outflow	--	--	--

Ratios

Profitability Ratios

	Akero Therapeutics (AKRO)	Leap Therapeutics (LPTX)	Adverum Biotechnologies (ADVM)
ROCE (%)	-37.39	-141.16	-86.23
ROE (%)	-28.69	-834.64	-189.84
ROA (%)	-30.60	-190.64	-107.81
EBIT Margin (%)	-7,205,162.50	-10,576.52	4,048.00
Net Margin (%)	-7,320,500.00	-22,170.65	5,677.56
Cash Profit Margin (%)	-488.03	--	0.00

Growth Ratios

	Akero Therapeutics (AKRO)	Leap Therapeutics (LPTX)	Adverum Biotechnologies (ADVM)
Revenue Growth (%)	-98.59	31.45	-38.46
EBIT Growth (%)	-23.77	26.65	-24.04
Net Profit Growth (%)	-23.44	-27.89	-88.39
EPS Growth (%)	-0.06	0.23	-97.54
Book Value Growth (%)	9.83	-94.53	-134.32

Valuation Ratios

	Akero Therapeutics (AKRO)	Leap Therapeutics (LPTX)	Adverum Biotechnologies (ADVM)
Price / Earnings	-7.79	-1.76	-0.74
Price / Book Value	2.62	3.38	1.38
Dividend Yield (%)	--	--	--
EV/EBITDA	-5.08	-1.02	-0.47
Market Cap ($ Cr)	--	--	--

Solvency Ratios

	Akero Therapeutics (AKRO)	Leap Therapeutics (LPTX)	Adverum Biotechnologies (ADVM)
Debt to Equity	0.00	0.00	0.00
Short term debt to equity ratio	0.00	0.01	-0.10
Current Ratio	15.83	1.21	0.65
Quick Ratio	15.83	1.21	0.65
Interest Coverage	-62.41	-4,357.87	--

Operating Efficiency Ratios

	Akero Therapeutics (AKRO)	Leap Therapeutics (LPTX)	Adverum Biotechnologies (ADVM)
Debtors to sales (%)	0.00	0.00	0.00
Asset Turnover	0.00	0.01	-0.02
Receivable days	--	--	--
Inventory Days	--	--	--
Payable days	162,992.81	409,372.20	176.53
Cash Conversion Cycle	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly